4-[5-(1H-indol-4-yl)-2-[[4-(4-methylpiperazin-1-yl)piperidin-1-yl]methyl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine

C29H38N8O — CID 140863792

IUPAC4-[5-(1H-indol-4-yl)-2-[[4-(4-methylpiperazin-1-yl)piperidin-1-yl]methyl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine
SMILESCN1CCN(C2CCN(Cc3cc4nc(-c5cccc6[nH]ccc56)cc(N5CCOCC5)n4n3)CC2)CC1
InChIInChI=1S/C29H38N8O/c1-33-11-13-35(14-12-33)23-6-9-34(10-7-23)21-22-19-28-31-27(24-3-2-4-26-25(24)5-8-30-26)20-29(37(28)32-22)36-15-17-38-18-16-36/h2-5,8,19-20,23,30H,6-7,9-18,21H2,1H3
InChIKeyVJNBWPAOLXJVEU-UHFFFAOYSA-N
MW514.68 g/mol
LogP2.93
Rot. Bonds5

About 4-[5-(1H-indol-4-yl)-2-[[4-(4-methylpiperazin-1-yl)piperidin-1-yl]methyl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine

4-[5-(1H-indol-4-yl)-2-[[4-(4-methylpiperazin-1-yl)piperidin-1-yl]methyl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine (PubChem CID 140863792) has the molecular formula C29H38N8O and a molecular weight of 514.68 g/mol. Its IUPAC name is 4-[5-(1H-indol-4-yl)-2-[[4-(4-methylpiperazin-1-yl)piperidin-1-yl]methyl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine.

Molecular Properties

Compound Name4-[5-(1H-indol-4-yl)-2-[[4-(4-methylpiperazin-1-yl)piperidin-1-yl]methyl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine
PubChem CID140863792
Molecular FormulaC29H38N8O
Molecular Weight514.68 g/mol
Exact Mass514.32
IUPAC Name4-[5-(1H-indol-4-yl)-2-[[4-(4-methylpiperazin-1-yl)piperidin-1-yl]methyl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine
SMILESCN1CCN(C2CCN(Cc3cc4nc(-c5cccc6[nH]ccc56)cc(N5CCOCC5)n4n3)CC2)CC1
InChIInChI=1S/C29H38N8O/c1-33-11-13-35(14-12-33)23-6-9-34(10-7-23)21-22-19-28-31-27(24-3-2-4-26-25(24)5-8-30-26)20-29(37(28)32-22)36-15-17-38-18-16-36/h2-5,8,19-20,23,30H,6-7,9-18,21H2,1H3
InChIKeyVJNBWPAOLXJVEU-UHFFFAOYSA-N
XLogP2.93
TPSA68.17 Ų
H-Bond Donors1
H-Bond Acceptors8
Rotatable Bonds5
Heavy Atoms38
Complexity

Lipinski Rule of Five

1 violation

RuleValue
MW ≤ 500514.68
LogP ≤ 52.93
H-Bond Donors ≤ 51
H-Bond Acceptors ≤ 108

Analyze 4-[5-(1H-indol-4-yl)-2-[[4-(4-methylpiperazin-1-yl)piperidin-1-yl]methyl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine with MolForge

Explore ADMET properties, 3D molecular structure, drug-likeness score, and discover similar compounds using our AI-powered platform.

Launch Full Analysis

Frequently Asked Questions

What is the IUPAC name of 4-[5-(1H-indol-4-yl)-2-[[4-(4-methylpiperazin-1-yl)piperidin-1-yl]methyl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine?
The IUPAC name of 4-[5-(1H-indol-4-yl)-2-[[4-(4-methylpiperazin-1-yl)piperidin-1-yl]methyl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine (CID 140863792) is 4-[5-(1H-indol-4-yl)-2-[[4-(4-methylpiperazin-1-yl)piperidin-1-yl]methyl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine.
What is the SMILES notation for 4-[5-(1H-indol-4-yl)-2-[[4-(4-methylpiperazin-1-yl)piperidin-1-yl]methyl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine?
The canonical SMILES for 4-[5-(1H-indol-4-yl)-2-[[4-(4-methylpiperazin-1-yl)piperidin-1-yl]methyl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine is CN1CCN(C2CCN(Cc3cc4nc(-c5cccc6[nH]ccc56)cc(N5CCOCC5)n4n3)CC2)CC1.
What is the InChIKey of 4-[5-(1H-indol-4-yl)-2-[[4-(4-methylpiperazin-1-yl)piperidin-1-yl]methyl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine?
The InChIKey is VJNBWPAOLXJVEU-UHFFFAOYSA-N. The full InChI is InChI=1S/C29H38N8O/c1-33-11-13-35(14-12-33)23-6-9-34(10-7-23)21-22-19-28-31-27(24-3-2-4-26-25(24)5-8-30-26)20-29(37(28)32-22)36-15-17-38-18-16-36/h2-5,8,19-20,23,30H,6-7,9-18,21H2,1H3.
What are the key properties of 4-[5-(1H-indol-4-yl)-2-[[4-(4-methylpiperazin-1-yl)piperidin-1-yl]methyl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine?
4-[5-(1H-indol-4-yl)-2-[[4-(4-methylpiperazin-1-yl)piperidin-1-yl]methyl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine has a molecular weight of 514.68 g/mol, XLogP of 2.93, 5 rotatable bonds, 1 hydrogen bond donors, and 8 hydrogen bond acceptors.
Where does this data come from?
All data for 4-[5-(1H-indol-4-yl)-2-[[4-(4-methylpiperazin-1-yl)piperidin-1-yl]methyl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine is sourced from PubChem (CID 140863792), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).